Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies.

Autor: Al-Khayri, Jameel M.¹ (AUTHOR) jmjkhayri@kfu.edu.sa, Ravindran, Mamtha² (AUTHOR) mamtha.r@jainuniversity.ac.in, Banadka, Akshatha² (AUTHOR) b.akshatha@jainuniversity.ac.in, Vandana, Chendanda Devaiah² (AUTHOR) vandana.cd@jainuniversity.ac.in, Priya, Kushalva² (AUTHOR) kushalvapriya@gmail.com, Nagella, Praveen³ (AUTHOR) jmjkhayri@kfu.edu.sa, Kukkemane, Kowshik³ (AUTHOR)

Publikováno v: Pharmaceuticals (14248247). Oct2024, Vol. 17 Issue 10, p1391. 21p.

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.

Autor: Glaenzel U; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.) ulrike.glaenzel@novartis.com., Jin Y; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Hansen R; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Schroer K; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Rahmanzadeh G; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Pfaar U; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Jaap van Lier J; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Borell H; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Meissner A; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Camenisch G; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.)., Zhao S; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.).

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2020 Oct; Vol. 48 (10), pp. 873-885. Date of Electronic Publication: 2020 Jul 14.

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.

Autor: Zuckermann, Marc^1,2,3 (AUTHOR) m.zuckermann@kitz-heidelberg.de, He, Chen⁴ (AUTHOR), Andrews, Jared⁴ (AUTHOR), Bagchi, Aditi⁵ (AUTHOR), Sloan-Henry, Roketa⁶ (AUTHOR), Bianski, Brandon⁷ (AUTHOR), Xie, Jia⁷ (AUTHOR), Wang, Yingzhe⁸ (AUTHOR), Twarog, Nathaniel⁹ (AUTHOR), Onar-Thomas, Arzu¹⁰ (AUTHOR), Ernst, Kati J.^1,3 (AUTHOR), Yang, Lei⁹ (AUTHOR), Li, Yong⁹ (AUTHOR), Zhu, Xiaoyan⁴ (AUTHOR), Ocasio, Jennifer K.⁴ (AUTHOR), Budd, Kaitlin M.^4,11 (AUTHOR), Dalton, James¹² (AUTHOR), Li, Xiaoyu¹² (AUTHOR), Chepyala, Divyabharathi⁹ (AUTHOR), Zhang, Junyuan⁴ (AUTHOR)

Publikováno v: Molecular Cancer. 6/7/2024, Vol. 23 Issue 1, p1-19. 19p.

Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.

Autor: Becquet M; Department of Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Laborde L, Texier C, Sterker D, Gschwind HP, Pfaar U, Wartmann M, O'Reilly TM, McSheehy PM

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2018 Aug; Vol. 29 (7), pp. 691-701.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.